

ROCRO is proud to present it's first newsletter to our department! This newsletter will showcase key achievements of our office for 2019.

ROCRO Mission Statement

ROCRO's mission is to be a high impact clinical research program focusing on Radiation Therapy and Immunotherapy. One of our goals is to increase extra mural funding for the clinical trials. The office aims to open multiple Investigator initiated trials (IITs) and publish high impact manuscripts with the clinical data. The office plans to initiate at least two cooperative group trials as a lead institution in next five years. We are constantly improving visibility of our clinical trials to enhance patient enrollments.

Dr. Silvia C Formenti was awarded **ASTRO 2019 Gold Medal** for her outstanding contribution to the field of Radiation Oncology. Dr. Formenti also received a **Level 2 DOD award for Breaking through immune resistance of HR+ Breast Cancer** and a **Level 3 DoD award for the study- Converting HR+ Breast Cancer into an Individualized Vaccine.**



Dr. Josephine Kang was awarded **Basic/Translational Science Award from ASTRO** and the abstract was featured in Best of ASTRO 2019 meeting - *VISTA Blockade Immunotherapy in a Multi-Modal Approach to Triple Negative Breast Cancer (TNBC) in MICE and IMPACT on Microbiome*. She was also awarded a **R01** for PSMAPET/MR guided Prostate SBRT, to start in 2020. She also received WCMC- **Abby J Cohen clinical scholar** award for her work on microbiome and immune correlates.




Dr. Daniel Vanderbilt was awarded **Dean's Diversity and Healthcare Disparity Research Award** for the Project- *Feasibility of pulmonary nodules screening at standard CTsim for breast cancer radiotherapy*. Dr. Formenti is the mentor for the award



Protocol #	Short Title	PI	Target Accrual	Patients Enrolled
1505016201	PBI	Dr. Formenti	284	170
1602017017	ART	Dr. Formenti	74	26
1607017434	BMS- NSCLC	Dr. Formenti	41	9
1708018471	VARIAN	Dr. Formenti/Dr. Kang	60	44
1710018694	SRS-Pembro	Dr. Formenti	41	3
1712018849	PORT-PC	Dr. Nagar	40	5
19-07020533	PRART	Dr. Formenti/Dr. Ng	400	3
1612017831	RISE-M	Dr. Nagar/ Dr. Rossi	30	4
1802019010	ViewRay	Dr. Kang/Dr. Formenti	30	30
1612017834	EISAI - Rectal Cancer	Dr. Formenti/Dr. Ng	10	2
1708018460	NRG GU003	Dr. Nagar	10	3
1606017369	Met. GU	Dr. Golden/Dr. Nagar	112	6
				305

Dr. Sandra Demaria was awarded the **John M. Yuhaw Award** by the Dept. of Radiation Oncology, University of Pennsylvania for impactful contributions to the field of Radiation Oncology/Biology. Dr. Demaria is also the **Chairperson-Elect to the Steering Committee of the AACR Cancer Immunology Working Group (CIMM)**. Dr. Demaria served as the **Chair for the 34th Annual Meeting for the Society for the Immunotherapy of Cancer (SITC) 2019.**





Dr. Higinia Cardenas was invited to be **chair for Radiation therapy for Primary Liver tumors task force** at ASTRO 2019. The proposed guidelines are the first ASTRO guideline on all primary liver tumors including hepatocellular carcinomas and intrahepatic cholangiocarcinomas.



Dr. Onyinye Balogun received **2019 Global Health Faculty Award** by ARRO in recognition of her mentorship of the trainees in the Radiation Oncology community as well as commitment to the service of the patients.



We have **six IITs** in pipeline which should be approved very soon- *Prostate Radio Ablation Guided by MRI Acquisition in metastatic prostate cancer (PRAGMA), The Irradiated Breast Tumor Cavity (IORT), Personalized Second Chance Breast Conservation (PSCBC), Combined Immunotherapies in Metastatic ER+ breast cancer (CIMER), Salvage HYPOfractionated RadioTherapy for Prostate Cancer (Salvage HYPOR Trial) and Phase II study of PSMA PET/MR guided SBRT with SIB for high risk prostate cancer.*



Wishing you all Happy Holidays and a splendid 2020!